Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Eltrombopag in Elderly Acute Myelogenous Leukemia (AML)
NCT01113502 · Abramson Cancer Center at Penn Medicine · PHASE1/PHASE2 · terminated · last registry update 2021-08-05 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Abramson Cancer Center at Penn Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MPL in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-07-22Also stopped (terminated): Roswell Park Cancer Institute, eltrombopag olamine (NCT01550185)
- 2020-11-24Results posted on the registry: Case Comprehensive Cancer Center, eltrombopag olamine (NCT02071901)
- 2020-11-03Also stopped (terminated): PrECOG, LLC., Phase I- Cytarabine & Eltrombopag + Phase II- Sequence A (NCT01656252)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision